<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://oncdata.com/article/5a13862c-8e21-4766-8118-450bf236b770</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T12:49:57.984Z</news:publication_date><news:title>Evidence Is Insufficient to Show MPNST Surveillance Improves Outcomes in NF1: Review</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/59af50bb-9979-4d3a-92ad-8b2419ea1fad</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T12:49:57.882Z</news:publication_date><news:title>Phase I Trial of CD19 CAR-T Cells With PD1/CD28 Switch Receptor in R/R B-Cell Lymphoma</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/8113d491-eab7-4f1c-9b99-2cbbfdfaca68</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T02:49:20.711Z</news:publication_date><news:title>Th17-Based Model and Biomarkers Stratify Severe irAE Risk in Advanced NSCLC</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/c6e1146a-52cc-4852-a82c-f3ada730e28e</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-21T02:49:20.570Z</news:publication_date><news:title>TACE Plus Immunotherapy Versus TACE Alone in Unresectable Hepatocellular Carcinoma</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/3a6a28fa-cabb-4481-a705-96bebdb370c5</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T22:49:27.752Z</news:publication_date><news:title>TP53 (Investigational) Y220C Prevalence, Survival Impact, and Genomic Landscape in Ovarian Cancer</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/7e5d6134-fe38-4452-b3da-b0683f74a6e1</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-20T02:49:20.662Z</news:publication_date><news:title>Cabozantinib Starting Dose in Metastatic Renal Cell Carcinoma</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/4a767260-6aeb-45e8-8ed2-785593052e7d</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:49:23.456Z</news:publication_date><news:title>Precision Medicine in Genitourinary Cancers</news:title></news:news></url>
  <url><loc>https://oncdata.com/article/3c7c1556-e37c-49c4-9368-1ca7f4b99b6a</loc><news:news><news:publication><news:name>Oncology Data Advisor</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-19T22:49:23.401Z</news:publication_date><news:title>MACE Incidence Did Not Differ Across TKIs in Chronic Myelogenous Leukemia</news:title></news:news></url>
</urlset>